COVID-19

News

AZ expands phase 3 trials of COVID-19 vaccine frontrunner in...

AstraZeneca has expanded development of COVID-19 vaccine AZD1222 into the US, beginning a phase 3 clinical trial across all adult age groups.

News

Sanofi/Regeneron's Kevzara fails again in serious COVID-19 c...

Sanofi has drawn another blank in its attempt to repurpose its IL-6 drug Kevzara to tackle the extreme immune reaction seen in serious cases of COVID-19.

White Papers

COVID-19’s lasting impact on digital communication in health...

The ongoing digital transformation of the healthcare and pharmaceutical industries has been greatly accelerated during the coronavirus pandemic.

News

Moderna’s COVID vaccine works in older people, according to ...

Moderna has said that its coronavirus vaccine stimulated an immune response in older people in phase 1 trials, suggesting that the jab is effective in the age groups most susceptible to COVID-19

R&D

Close up of examining of test sample under the microscope in laboratory.

COVID-19 is causing a renaissance in the UK biotech sector, ...

Despite the UK’s world class research output and the many start-ups successfully spinning out from its academic institutions, in recent years UK biotech companies have struggled to access t

R&D

Alnylam, gene-silencing and biotech in 2020: the pharmaphoru...

Alnylam's Brendan Martin joined the pharmaphorum podcast for episode 23 to talk about his company's work in gene-silencing and how it could offer a route to target the current coronavirus p

AZ expands phase 3 trials of COVID-19 vaccine frontrunner in...

Sanofi/Regeneron's Kevzara fails again in serious COVID-19 c...

COVID-19’s lasting impact on digital communication in health...

Moderna’s COVID vaccine works in older people, according to ...

COVID-19 is causing a renaissance in the UK biotech sector, ...

Alnylam, gene-silencing and biotech in 2020: the pharmaphoru...

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

COVID-19

Editor's Picks